-
1
-
-
79551576468
-
Mechanisms of endocrine resistance in breast cancer
-
Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233-47.
-
(2011)
Annu Rev Med
, vol.62
, pp. 233-247
-
-
Osborne, C.K.1
Schiff, R.2
-
2
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
-
Ebctcg, Ebctcg: Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-717.
-
(2005)
Lancet
, vol.365
, pp. 1687-1717
-
-
-
3
-
-
0028861402
-
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
-
Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 1995;345:29-30.
-
(1995)
Lancet
, vol.345
, pp. 29-30
-
-
Howell, A.1
DeFriend, D.2
Robertson, J.3
Blamey, R.4
Walton, P.5
-
4
-
-
0034663421
-
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen
-
Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer. 2000;89:817-25.
-
(2000)
Cancer
, vol.89
, pp. 817-825
-
-
Howell, A.1
Osborne, C.K.2
Morris, C.3
Wakeling, A.E.4
-
5
-
-
0038683988
-
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials
-
Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003;98:229-38.
-
(2003)
Cancer
, vol.98
, pp. 229-238
-
-
Robertson, J.F.1
Osborne, C.K.2
Howell, A.3
Jones, S.E.4
Mauriac, L.5
Ellis, M.6
-
6
-
-
0029075872
-
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
-
Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995;87:746-50.
-
(1995)
J Natl Cancer Inst
, vol.87
, pp. 746-750
-
-
Osborne, C.K.1
Coronado-Heinsohn, E.B.2
Hilsenbeck, S.G.3
McCue, B.L.4
Wakeling, A.E.5
McClelland, R.A.6
-
7
-
-
69249137029
-
Biological determinants of endocrine resistance in breast cancer
-
Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9:631-43.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 631-643
-
-
Musgrove, E.A.1
Sutherland, R.L.2
-
8
-
-
0028329961
-
Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1
-
Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res. 1994;54:1587-95.
-
(1994)
Cancer Res
, vol.54
, pp. 1587-1595
-
-
Lykkesfeldt, A.E.1
Madsen, M.W.2
Briand, P.3
-
9
-
-
0029059562
-
Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment
-
Lykkesfeldt AE, Larsen SS, Briand P. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer. 1995;61:529-34.
-
(1995)
Int J Cancer
, vol.61
, pp. 529-534
-
-
Lykkesfeldt, A.E.1
Larsen, S.S.2
Briand, P.3
-
10
-
-
0031051458
-
Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells
-
Madsen MW, Reiter BE, Larsen SS, Briand P, Lykkesfeldt AE. Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res. 1997;57:585-9.
-
(1997)
Cancer Res
, vol.57
, pp. 585-589
-
-
Madsen, M.W.1
Reiter, B.E.2
Larsen, S.S.3
Briand, P.4
Lykkesfeldt, A.E.5
-
11
-
-
84893698272
-
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant
-
Kirkegaard T, Hansen SK, Larsen SL, Reiter BE, Sorensen BS, Lykkesfeldt AE. T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant. Cancer Lett. 2014;344:90-100.
-
(2014)
Cancer Lett
, vol.344
, pp. 90-100
-
-
Kirkegaard, T.1
Hansen, S.K.2
Larsen, S.L.3
Reiter, B.E.4
Sorensen, B.S.5
Lykkesfeldt, A.E.6
-
12
-
-
59449093537
-
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant
-
Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat. 2009;114:263-75.
-
(2009)
Breast Cancer Res Treat
, vol.114
, pp. 263-275
-
-
Frogne, T.1
Benjaminsen, R.V.2
Sonne-Hansen, K.3
Sorensen, B.S.4
Nexo, E.5
Laenkholm, A.V.6
-
13
-
-
77953119642
-
Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance
-
Sonne-Hansen K, Norrie IC, Emdal KB, Benjaminsen RV, Frogne T, Christiansen IJ, et al. Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance. Breast Cancer Res Treat. 2010;121:601-13.
-
(2010)
Breast Cancer Res Treat
, vol.121
, pp. 601-613
-
-
Sonne-Hansen, K.1
Norrie, I.C.2
Emdal, K.B.3
Benjaminsen, R.V.4
Frogne, T.5
Christiansen, I.J.6
-
14
-
-
84877582872
-
Estrogen receptor alpha is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling
-
Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS, Yde CW. Estrogen receptor alpha is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat. 2013;139:71-80.
-
(2013)
Breast Cancer Res Treat
, vol.139
, pp. 71-80
-
-
Thrane, S.1
Lykkesfeldt, A.E.2
Larsen, M.S.3
Sorensen, B.S.4
Yde, C.W.5
-
15
-
-
58249105933
-
ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and p90RSK
-
Pancholi S, Lykkesfeldt A, Hilmi C, Banerjee S, Leary A, Drury S, et al. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and p90RSK. EndocrRelat Cancer. 2008;15:985-1002.
-
(2008)
EndocrRelat Cancer
, vol.15
, pp. 985-1002
-
-
Pancholi, S.1
Lykkesfeldt, A.2
Hilmi, C.3
Banerjee, S.4
Leary, A.5
Drury, S.6
-
16
-
-
0037534310
-
Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines
-
Sommer A, Hoffmann J, Lichtner RB, Schneider MR, Parczyk K. Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines. J Steroid Biochem Mol Biol. 2003;85:33-47.
-
(2003)
J Steroid Biochem Mol Biol
, vol.85
, pp. 33-47
-
-
Sommer, A.1
Hoffmann, J.2
Lichtner, R.B.3
Schneider, M.R.4
Parczyk, K.5
-
17
-
-
0034987631
-
Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex)
-
McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology. 2001;142:2776-88.
-
(2001)
Endocrinology
, vol.142
, pp. 2776-2788
-
-
McClelland, R.A.1
Barrow, D.2
Madden, T.A.3
Dutkowski, C.M.4
Pamment, J.5
Knowlden, J.M.6
-
18
-
-
38849091433
-
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
-
Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008;68:826-33.
-
(2008)
Cancer Res
, vol.68
, pp. 826-833
-
-
Massarweh, S.1
Osborne, C.K.2
Creighton, C.J.3
Qin, L.4
Tsimelzon, A.5
Huang, S.6
-
19
-
-
37049183697
-
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-82.
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
Levin, W.J.4
Ullrich, A.5
McGuire, W.L.6
-
20
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
-
21
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-72.
-
(2005)
N Engl J Med
, vol.353
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
Goldhirsch, A.4
Untch, M.5
Smith, I.6
-
22
-
-
84870192369
-
The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis
-
Carmena M, Wheelock M, Funabiki H, Earnshaw WC. The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol. 2012;13:789-803.
-
(2012)
Nat Rev Mol Cell Biol
, vol.13
, pp. 789-803
-
-
Carmena, M.1
Wheelock, M.2
Funabiki, H.3
Earnshaw, W.C.4
-
23
-
-
33846809037
-
DNA methylation promotes Aurora-B-driven phosphorylation of histone H3 in chromosomal subdomains
-
Monier K, Mouradian S, Sullivan KF. DNA methylation promotes Aurora-B-driven phosphorylation of histone H3 in chromosomal subdomains. J Cell Sci. 2007;120:101-14.
-
(2007)
J Cell Sci
, vol.120
, pp. 101-114
-
-
Monier, K.1
Mouradian, S.2
Sullivan, K.F.3
-
24
-
-
1642403599
-
Cell cycle-dependent regulation of the human aurora B promoter
-
Kimura M, Uchida C, Takano Y, Kitagawa M, Okano Y. Cell cycle-dependent regulation of the human aurora B promoter. Biochem Biophys Res Commun. 2004;316:930-6.
-
(2004)
Biochem Biophys Res Commun
, vol.316
, pp. 930-936
-
-
Kimura, M.1
Uchida, C.2
Takano, Y.3
Kitagawa, M.4
Okano, Y.5
-
26
-
-
70249098518
-
Clinical experience with aurora kinase inhibitors: a review
-
Boss DS, Beijnen JH, Schellens JH. Clinical experience with aurora kinase inhibitors: a review. Oncologist. 2009;14:780-93.
-
(2009)
Oncologist
, vol.14
, pp. 780-793
-
-
Boss, D.S.1
Beijnen, J.H.2
Schellens, J.H.3
-
27
-
-
41549122837
-
Aurora kinases as anticancer drug targets
-
Gautschi O, Heighway J, Mack PC, Purnell PR, Lara Jr PN, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008;14:1639-48.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 1639-1648
-
-
Gautschi, O.1
Heighway, J.2
Mack, P.C.3
Purnell, P.R.4
Lara, P.N.5
Gandara, D.R.6
-
28
-
-
84938954940
-
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells
-
Thrane S, Pedersen AM, Thomsen MB, Kirkegaard T, Rasmussen BB, Duun-Henriksen AK, Laenkholm AV, Bak M, Lykkesfeldt AE, Yde CW: A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. Oncogene 2014; doi: 10.1038/onc.2014.351.
-
(2014)
Oncogene
-
-
Thrane, S.1
Pedersen, A.M.2
Thomsen, M.B.3
Kirkegaard, T.4
Rasmussen, B.B.5
Duun-Henriksen, A.K.6
Laenkholm, A.V.7
Bak, M.8
Lykkesfeldt, A.E.9
Yde, C.W.10
-
29
-
-
0034866694
-
Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways
-
Lundholt BK, Briand P, Lykkesfeldt AE. Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat. 2001;67:199-214.
-
(2001)
Breast Cancer Res Treat
, vol.67
, pp. 199-214
-
-
Lundholt, B.K.1
Briand, P.2
Lykkesfeldt, A.E.3
-
30
-
-
50649117316
-
The regulatory beta-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis
-
Yde CW, Olsen BB, Meek D, Watanabe N, Guerra B. The regulatory beta-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis. Oncogene. 2008;27:4986-97.
-
(2008)
Oncogene
, vol.27
, pp. 4986-4997
-
-
Yde, C.W.1
Olsen, B.B.2
Meek, D.3
Watanabe, N.4
Guerra, B.5
-
31
-
-
34250740430
-
Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death
-
Yde CW, Gyrd-Hansen M, Lykkesfeldt AE, Issinger OG, Stenvang J. Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Mol Cancer Ther. 2007;6:1869-76.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 1869-1876
-
-
Yde, C.W.1
Gyrd-Hansen, M.2
Lykkesfeldt, A.E.3
Issinger, O.G.4
Stenvang, J.5
-
32
-
-
45149090757
-
The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise
-
Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47:506-24.
-
(2008)
Acta Oncol
, vol.47
, pp. 506-524
-
-
Moller, S.1
Jensen, M.B.2
Ejlertsen, B.3
Bjerre, K.D.4
Larsen, M.5
Hansen, H.B.6
-
33
-
-
67549088394
-
Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors
-
Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res. 2009;11:R11.
-
(2009)
Breast Cancer Res
, vol.11
, pp. R11
-
-
Frogne, T.1
Laenkholm, A.V.2
Lyng, M.B.3
Henriksen, K.L.4
Lykkesfeldt, A.E.5
-
34
-
-
0034604354
-
Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes
-
Hsu JY, Sun ZW, Li X, Reuben M, Tatchell K, Bishop DK, et al. Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell. 2000;102:279-91.
-
(2000)
Cell
, vol.102
, pp. 279-291
-
-
Hsu, J.Y.1
Sun, Z.W.2
Li, X.3
Reuben, M.4
Tatchell, K.5
Bishop, D.K.6
-
35
-
-
77649305739
-
Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer
-
Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, et al. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer. 2010;9:42.
-
(2010)
Mol Cancer
, vol.9
, pp. 42
-
-
Gully, C.P.1
Zhang, F.2
Chen, J.3
Yeung, J.A.4
Velazquez-Torres, G.5
Wang, E.6
-
36
-
-
33244490241
-
Complex formation of Plk1 and INCENP required for metaphase-anaphase transition
-
Goto H, Kiyono T, Tomono Y, Kawajiri A, Urano T, Furukawa K, et al. Complex formation of Plk1 and INCENP required for metaphase-anaphase transition. Nat Cell Biol. 2006;8:180-7.
-
(2006)
Nat Cell Biol
, vol.8
, pp. 180-187
-
-
Goto, H.1
Kiyono, T.2
Tomono, Y.3
Kawajiri, A.4
Urano, T.5
Furukawa, K.6
-
37
-
-
85027947011
-
Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERalpha in breast cancer
-
Zheng XQ, Guo JP, Yang H, Kanai M, He LL, Li YY, et al. Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERalpha in breast cancer. Oncogene. 2014;33:4985-96.
-
(2014)
Oncogene
, vol.33
, pp. 4985-4996
-
-
Zheng, X.Q.1
Guo, J.P.2
Yang, H.3
Kanai, M.4
He, L.L.5
Li, Y.Y.6
-
38
-
-
84922594316
-
Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells
-
Hole S, Pedersen AM, Lykkesfeldt AE, Yde CW. Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells. Breast Cancer Res Treat. 2015;149:715-26.
-
(2015)
Breast Cancer Res Treat
, vol.149
, pp. 715-726
-
-
Hole, S.1
Pedersen, A.M.2
Lykkesfeldt, A.E.3
Yde, C.W.4
-
39
-
-
78649864566
-
Aurora kinase inhibitors as anticancer molecules
-
Katayama H, Sen S. Aurora kinase inhibitors as anticancer molecules. Biochim Biophys Acta. 2010;1799:829-39.
-
(2010)
Biochim Biophys Acta
, vol.1799
, pp. 829-839
-
-
Katayama, H.1
Sen, S.2
-
40
-
-
0037105758
-
Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability
-
Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res. 2002;62:5168-77.
-
(2002)
Cancer Res
, vol.62
, pp. 5168-5177
-
-
Ota, T.1
Suto, S.2
Katayama, H.3
Han, Z.B.4
Suzuki, F.5
Maeda, M.6
-
41
-
-
38349108184
-
The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma
-
Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, et al. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol. 2008;140:295-302.
-
(2008)
Br J Haematol
, vol.140
, pp. 295-302
-
-
Evans, R.P.1
Naber, C.2
Steffler, T.3
Checkland, T.4
Maxwell, C.A.5
Keats, J.J.6
-
42
-
-
34250739960
-
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis
-
Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 2007;13:3682-8.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 3682-3688
-
-
Wilkinson, R.W.1
Odedra, R.2
Heaton, S.P.3
Wedge, S.R.4
Keen, N.J.5
Crafter, C.6
-
43
-
-
66249093516
-
AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo
-
Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res. 2009;69:4150-8.
-
(2009)
Cancer Res
, vol.69
, pp. 4150-4158
-
-
Oke, A.1
Pearce, D.2
Wilkinson, R.W.3
Crafter, C.4
Odedra, R.5
Cavenagh, J.6
-
44
-
-
84879554441
-
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
-
Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, et al. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs. 2013;31:370-80.
-
(2013)
Invest New Drugs
, vol.31
, pp. 370-380
-
-
Schwartz, G.K.1
Carvajal, R.D.2
Midgley, R.3
Rodig, S.J.4
Stockman, P.K.5
Ataman, O.6
-
45
-
-
79251556865
-
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors
-
Boss DS, Witteveen PO, van der Sar J, Lolkema MP, Voest EE, Stockman PK, et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol. 2011;22:431-7.
-
(2011)
Ann Oncol
, vol.22
, pp. 431-437
-
-
Boss, D.S.1
Witteveen, P.O.2
Sar, J.3
Lolkema, M.P.4
Voest, E.E.5
Stockman, P.K.6
-
46
-
-
80052100694
-
A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia
-
Tsuboi K, Yokozawa T, Sakura T, Watanabe T, Fujisawa S, Yamauchi T, et al. A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. Leuk Res. 2011;35:1384-9.
-
(2011)
Leuk Res
, vol.35
, pp. 1384-1389
-
-
Tsuboi, K.1
Yokozawa, T.2
Sakura, T.3
Watanabe, T.4
Fujisawa, S.5
Yamauchi, T.6
-
47
-
-
82955217793
-
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
-
Lowenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, et al. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood. 2011;118:6030-6.
-
(2011)
Blood
, vol.118
, pp. 6030-6036
-
-
Lowenberg, B.1
Muus, P.2
Ossenkoppele, G.3
Rousselot, P.4
Cahn, J.Y.5
Ifrah, N.6
-
48
-
-
24644497683
-
Rapid estrogen-induced phosphorylation of the SRC-3 coactivator occurs in an extranuclear complex containing estrogen receptor
-
Zheng FF, Wu RC, Smith CL, O'Malley BW. Rapid estrogen-induced phosphorylation of the SRC-3 coactivator occurs in an extranuclear complex containing estrogen receptor. Mol Cell Biol. 2005;25:8273-84.
-
(2005)
Mol Cell Biol
, vol.25
, pp. 8273-8284
-
-
Zheng, F.F.1
Wu, R.C.2
Smith, C.L.3
O'Malley, B.W.4
-
49
-
-
84862644315
-
High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer
-
Erpolat OP, Gocun PU, Akmansu M, Karakus E, Akyol G. High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer. Strahlen ther Onkol. 2012;188:248-54.
-
(2012)
Strahlen ther Onkol
, vol.188
, pp. 248-254
-
-
Erpolat, O.P.1
Gocun, P.U.2
Akmansu, M.3
Karakus, E.4
Akyol, G.5
|